Fig. 4.1
Office BP values at follow-up. Changes in average office BP (a) and mean decrease in office BP (b) at follow-up. Error bars represent SDs. *P < 0.001 versus baseline (before the procedure). FU follow-up, M month, pre-RDN prerenal denervation. (Reprinted from [53]. With permission from the American Society of Nephrology)
Some concerns of this methodology specifically for CKD patients have to considered. First, in patients with low GFR renal blood flow can be particularly reduced. Since cooling of the catheter tip depends decisively on the blood flow, thermal problems might occur increasing the potential for damage of the renal blood vessels. Second, the procedure requires substantial amounts of contrast media raising the risk of acute kidney injury in these patients. Of interest, Hering et al. observed no deterioration in renal function over the course of the study in CKD patients.
The Simplicity Study III, a randomized controlled study, failed to demonstrate a beneficial effect of renal denervation on BP in a large group of patients with resistant hypertension [54]. Given these unimpressive results, the role of renal denervation in the management of resistant hypertension, particularly in CKD patients, remains to be established. Several issues need to be resolved: first, how to identify patients with increased renal sympathetic nerve activity , who may be more suitable for renal denervation; second, to what extent and with what variability renal denervation is achieved with the Simplicity catheter by various investigators; third, the issue of regeneration of renal nerves after denervation remains unresolved. Until all these issues are satisfactorily resolved, renal denervation should remain an experimental tool in the management of hypertension associated with kidney disease .
References
1.
3.
4.
5.
6.
Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol. 1994;4:1901–7.PubMed
7.
8.
9.
10.
Lake CR, Ziegler MG, Coleman MD, Kopin IJ. Plasma levels of norepinephrine and dopamine-beta-hydroxylase in CRF patients treated with dialysis. Cardiovasc Med. 1979;1:1099–111.
11.
12.
Lzzo JL, Izzo MS, Sterns RH, Freeman RB. Sympathetic nervous system hyperactivity in maintenance hemodialysis patients. Trans Am Soc Artif Intern Organs. 1982;28:604–7.
13.
14.
15.
16.
Grekas D, Kalevrosoglou I, Karamouzis M, et al. Effects of sympathetic and plasma renin activity on hemodialysis hypertension. Clin Nephrol. 2001;55:115–20.PubMed
17.
Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.CrossRefPubMed